Literature DB >> 20648624

PED interacts with Rac1 and regulates cell migration/invasion processes in human non-small cell lung cancer cells.

Ciro Zanca1, Flora Cozzolino, Cristina Quintavalle, Stefania Di Costanzo, Lucia Ricci-Vitiani, Margherita Santoriello, Maria Monti, Piero Pucci, Gerolama Condorelli.   

Abstract

PED (phosphoprotein enriched in diabetes) is a 15 kDa protein involved in many cellular pathways and human diseases including type II diabetes and cancer. We recently reported that PED is overexpressed in human cancers and mediates resistance to induced apoptosis. To better understand its role in cancer, we investigated on PED interactome in non-small cell lung cancer (NSCLC). By the Tandem Affinity Purification (TAP), we identified and characterized among others, Rac1, a member of mammalian Rho GTPase protein family, as PED-interacting protein. In this study we show that PED coadiuvates Rac1 activation by regulating AKT mediated Rac1-Ser(71) phosphorylation. Furthermore, we show that the expression of a constitutively active Rac, affected PED-Ser(104) phosphorylation, which is important for PED-regulated ERK 1/2 nuclear localization. Through specific Rac1-siRNA or its pharmacological inhibition, we demonstrate that PED augments migration and invasion in a Rac1-dependent manner in NSCLC. In conclusion, we show for the first time that PED and Rac1 interact and that this interaction modulates cell migration/invasion processes in cancer cells through ERK1/2 pathway. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20648624     DOI: 10.1002/jcp.22197

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Modulation of dendritic spines and synaptic function by Rac1: a possible link to Fragile X syndrome pathology.

Authors:  Odelia Y N Bongmba; Luis A Martinez; Mary E Elhardt; Karlis Butler; Maria V Tejada-Simon
Journal:  Brain Res       Date:  2011-05-17       Impact factor: 3.252

2.  Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells.

Authors:  Cristina Quintavalle; Stefania Di Costanzo; Ciro Zanca; Immaculada Tasset; Alessandro Fraldi; Mariarosaria Incoronato; Peppino Mirabelli; Maria Monti; Andrea Ballabio; Piero Pucci; Ana Maria Cuervo; Gerolama Condorelli
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

3.  Three-dimensional patterning of multiple cell populations through orthogonal genetic control of cell motility.

Authors:  Joanna L MacKay; Anshum Sood; Sanjay Kumar
Journal:  Soft Matter       Date:  2014-04-14       Impact factor: 3.679

4.  MicroRNA-212 displays tumor-promoting properties in non-small cell lung cancer cells and targets the hedgehog pathway receptor PTCH1.

Authors:  Yuan Li; Deqiang Zhang; Chengwen Chen; Zhenchao Ruan; Yao Li; Yan Huang
Journal:  Mol Biol Cell       Date:  2012-02-22       Impact factor: 4.138

5.  PED/PEA-15 interacts with the 67 kD laminin receptor and regulates cell adhesion, migration, proliferation and apoptosis.

Authors:  Pietro Formisano; Pia Ragno; Ada Pesapane; Daniela Alfano; Anna Teresa Alberobello; Vincenza Elena Anna Rea; Raffaella Giusto; Francesca W Rossi; Francesco Beguinot; Guido Rossi; Nunzia Montuori
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

Review 6.  Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.

Authors:  Fiona H Greig; Graeme F Nixon
Journal:  Pharmacol Ther       Date:  2014-03-20       Impact factor: 12.310

7.  Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.

Authors:  Cristina Quintavalle; Sravanth Kumar Hindupur; Luca Quagliata; Pierlorenzo Pallante; Cecilia Nigro; Gerolama Condorelli; Jesper Bøje Andersen; Katrin Elisabeth Tagscherer; Wilfried Roth; Francesco Beguinot; Markus Hermann Heim; Charlotte Kiu Yan Ng; Salvatore Piscuoglio; Matthias Sebastian Matter
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

Review 8.  Insights on CXC chemokine receptor 2 in breast cancer: An emerging target for oncotherapy.

Authors:  Fengzhu Guo; Lang Long; Jiantao Wang; Yuyi Wang; Yanyang Liu; Li Wang; Feng Luo
Journal:  Oncol Lett       Date:  2019-10-03       Impact factor: 2.967

9.  Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.

Authors:  Margherita Iaboni; Valentina Russo; Raffaela Fontanella; Giuseppina Roscigno; Danilo Fiore; Elvira Donnarumma; Carla Lucia Esposito; Cristina Quintavalle; Paloma H Giangrande; Vittorio de Franciscis; Gerolama Condorelli
Journal:  Mol Ther Nucleic Acids       Date:  2016-03-08       Impact factor: 10.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.